Senior Vice President, Corporate Development
Lyn Baranowski joined Melinta Therapeutics in September 2013 as senior vice president, corporate development and strategy, bringing to the company her deep life sciences industry experience spanning biotech, pharmaceuticals and venture capital.
Prior to joining Melinta, Ms. Baranowski was vice president of commercial development at Pearl Therapeutics and was instrumental in driving the company’s corporate development activities including its recent sale to AstraZeneca. Before her role at Pearl Therapeutics, Ms. Baranowski served as vice president of Vatera Healthcare Partners, a healthcare-focused venture capital firm based in New York, where she was responsible for lead identification, evaluation, and negotiation as well as working with management teams of portfolio companies to develop and implement business plans. Ms. Baranowski previously held public affairs, business development and commercial executive roles at Novartis, including leading the launch of the osteoporosis drug Reclast®.
Ms. Baranowski holds an MBA from Harvard Business School and a B.A. from American University.